What Renflexis Pricing Says About Medicare's Biosimilars Policy
Launch of a second infliximab biosimilar by Merck triggers Medicare's controversial biosimilars reimbursement policy for the first time.
Launch of a second infliximab biosimilar by Merck triggers Medicare's controversial biosimilars reimbursement policy for the first time.